+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pneumococcal Vaccines Market - Forecasts from 2019 to 2024

  • ID: 4801627
  • Report
  • 107 pages
  • Knowledge Sourcing Intelligence LLP
1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Baxter International
  • GSK
  • Merck
  • Pfizer
  • Sanofi Pasteur MSD
  • MORE
The Pneumococcal vaccines market is estimated to witness a CAGR of 4.74% to reach US$10,618.805 million in 2024 from US$8,044.052 million in 2018. Pneumococcal diseases affect thousands of people every year as it is a contagious disease and can easily spread from person to person these rising incidences of pneumococcal diseases like pneumonia, meningitis, febrile bacteremia, otitis media, sinusitis, bronchitis, and others is driving the demand for pneumococcal vaccines. Pneumococcal vaccines may or may not protect against the pneumonia disease but they can reduce the effect of this disease.

The market is also being driven by the strong support of the local government and private health organizations such as UNICEF, WHO and U.S Centers for Disease Control and Prevention has recommended the pneumococcal vaccines to all the children below 2 years of age and adults above 65. According to WHO, the pneumococcal vaccine had been introduced in 134 countries by 2016 end and estimated global coverage was about 42%. Growing awareness regarding the importance of vaccination and increasing spending by the governments towards public health is fuelling the development of pneumococcal vaccines in developing countries. However, there are some side effects after getting vaccinated but there is a very low chance of getting any serious reaction.

Drivers

Increase in the number of pneumococcal diseases.

Favorable support by the government.

OPPORTUNITY
Pneumococcal vaccine is being introduced in cancer treatment for making antibodies to fight cancer.

Industry Update

In February 2019, Pfizer accounted to investigate Serotype included in 20- Valent Pneumococcal Conjugate vaccine candidate for the prevention of Invasive disease and Pneumonia in Adults aged 18 years or above.

In May 2017, Pfizer’s pneumonia vaccine became part of the immunization program.

The major players profiled in the pneumococcal vaccines market include Pfizer, Sanofi Pasteur MSD, GSK, Merck, AstraZeneca, and Baxter International.

Segmentation

The Pneumococcal vaccines market has been analyzed through the following segments:

By Type
Conjugate vaccines
Polysaccharide vaccines

By Application
Routine Vaccination
Vaccination for Disease/ Infection

By Geography
North America
USA
Canada
Mexico

South America
Brazil
Argentina
Others

Europe
Germany
France
United Kingdom
Spain
Others

Middle East and Africa
Saudi Arabia
Israel
Others

Asia Pacific
China
Japan
South Korea
India
Others
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Baxter International
  • GSK
  • Merck
  • Pfizer
  • Sanofi Pasteur MSD
  • MORE
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources

3. KEY FINDINGS

4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter's Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. PNEUMOCOCCAL VACCINES MARKET BY TYPE
5.1. Conjugate Vaccine
5.2. Polysaccharide Vaccine

6. PNEUMOCOCCAL VACCINES MARKET BY APPLICATION
6.1. Routine Vaccination
6.2. Vaccination for Disease/ Infection

7. PNEUMOCOCCAL VACCINES MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others

8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players

9. COMPANY PROFILES
9.1. Pfizer
9.2. Sanofi Pasteur MSD
9.3. GSK
9.4. Merck
9.5. AstraZeneca
9.6. Baxter International
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer
  • Sanofi Pasteur MSD
  • GSK
  • Merck
  • AstraZeneca
  • Baxter International
Note: Product cover images may vary from those shown
5 of 4

The research study is based on the publisher's proprietary research model. The process involves sourcing of information from various industry experts, key professionals, decision-makers and various other stakeholders along with the validation of the responses received from the vast in-house database and premium paid databases. Publicly available sources were also taken into consideration for the final market estimates and forecast for the segments and sub-segments.

The first phase of the research process is the identification of key industry leaders, experts, decision-makers and C-level executives and then conducting interviews and surveys to gain vital insights about the market. Simultaneously, extensive secondary research is done, and key secondary data is collected as part of this process. This secondary data is collected from various databases, industry journals, whitepapers, company annual reports, research publications, and other paid data sources and relevant literature. Company profiles which include strategies, new product developments, recent investments, major products and services, financials and business plans are sourced from the annual reports, SEC filings, industry associations to preserve the quality of the information being displayed. The findings from both the primary and the secondary research process combined go under further processing for market breakdown and forecasting.

The last phase is providing intelligence in the form of presentation, charts, graphics and other different formats helping the clients in a faster and efficient understanding of the market. Under this phase complete market engineering is involved which includes analyzing the collected data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting. The publisher has developed their market forecasting methodology that, in addition to the main market values, also takes into account other macroeconomic factors (global or local) that might have some bearing on the market under study. Taking all the necessary data, a robust forecast is developed using an algorithm that involves both static (multivariate) as well as dynamic (time-series) regression analysis. Special care is taken to make sure their algorithm passes the necessary statistical tests, and the mean prediction for future years obtained is reliable with a very high confidence level. Following data validation, the analysts begin to write the report presenting insights with the help of charts, graphs, and tables.

 

Loading
LOADING...

Adroll
adroll